Cymabay Therapeutics Gross Profit

Cymabay Therapeutics (CBAY) currently reports a gross profit of $30M as of December 2023. That compares with $-540K in the prior-year period — up 5717.7% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore Cymabay Therapeutics's gross profit history and peer comparisons.

Cymabay Therapeutics's gross profit increased from $-540K to $30M — a 5717.7% year-over-year increase (period ending December 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Cymabay Therapeutics's gross profit of $30M is lower than the Healthcare sector average of $66B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Cymabay Therapeutics reported $30M in gross profit as of December 2023. That compares with $-540K in the prior-year period — up 5717.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $30M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for Cymabay Therapeutics, and consider following CBAY for alerts when major investors trade the stock.